. Author manuscript; available in PMC: 2021 May 19.

Published in final edited form as: Cancer Lett. 2018 Oct 10;440-441:82–93. doi: 10.1016/j.canlet.2018.10.007

Table 3.

Selonsertib sensitized ABCG2-substrate-selected resistant cell lines to ABCG2 substrates.

Treatment	IC₅₀ ± SD^a (RF^b)
	NCI-H460 (μM)	NCI-H460/MX20 (μM)	S1 (μM)	S1-M1–80 (μΜ)
Mitoxantrone	0.038 ± 0.003 (1.00)	5.139 ± 0.801 (135.01)	0.033 ± 0.007 (1.00)	2.700 ± 0.711 (81.52)
+Selonsertib (3 μM)	0.031 ± 0.001 (0.82)	0.557 ± 0.036 (14.63)^*	0.033 ± 0.014 (0.99)	0.540 ± 0.521 (16.30)^*
+Selonsertib (10 μM)	0.027 ± 0.002 (0.71)	0.385 ± 0.061 (10.12)^*	0.034 ± 0.009 (1.03)	0.133 ± 0.082 (4.01)^*
+Ko 143 (10 μM)	0.030 ± 0.001 (0.80)	0.428 ± 0.091 (11.24)^*	0.036 ± 0.015 (1.08)	0.064 ± 0.018 (1.92)^*
SN-38	0.039 ± 0.009 (1.00)	3.493 ± 0.129 (88.80)	0.047 ± 0.006 (1.00)	2.336 ± 0.345 (50.04)
+Selonsertib (3 μM)	0.021 ± 0.002 (0.53)	0.463 ± 0.424 (11.77)^*	0.061 ± 0.005 (1.31)	1.346 ± 0.674 (28.83)^*
+Selonsertib (10 μM)	0.023 ± 0.006 (0.58)	0.178 ± 0.080 (4.51)^*	0.056 ± 0.013 (1.21)	0.421 ± 0.359 (9.02)^*
+Ko 143 (10 μM)	0.018 ± 0.004 (0.46)	0.104 ± 0.065 (2.65)^*	0.035 ± 0.014 (0.75)	0.076 ± 0.014 (1.63)^*
Topotecan	0.066 ± 0.003 (1.00)	4.113 ± 0.738 (62.72)	0.065 ± 0.002 (1.00)	2.492 ± 0.210 (38.54)
+Selonsertib (3 μM)	0.049 ± 0.001 (0.75)	0.909 ± 0.453 (13.86)^*	0.061 ± 0.004 (0.94)	1.167 ± 0.733 (18.05)^*
+Selonsertib (10 μM)	0.046 ± 0.002 (0.70)	0.311 ± 0.150 (4.74)^*	0.077 ± 0.023 (1.19)	0.168 ± 0.184 (2.60)^*
+Ko 143 (10 μM)	0.047 ± 0.002 (0.71)	0.212 ± 0.129 (3.23)^*	0.069 ± 0.004 (1.07)	0.197 ± 0.075 (3.05)^*
Cisplatin	2.061 ± 0.500 (1.00)	2.889 ± 0.861 (1.40)	1.770 ± 0.285 (1.00)	1.918 ± 0.462 (1.08)
+Selonsertib (3 μM)	1.580 ± 0.281 (0.77)	2.928 ± 1.224 (1.42)	2.016 ± 0.262 (1.14)	2.169 ± 0.304 (1.23)
+Selonsertib (10 μM)	1.621 ± 0.165 (0.79)	2.813 ± 0.695 (1.37)	2.268 ± 0.212 (1.28)	2.325 ± 0.283 (1.31)
+Ko 143 (10 μM)	2.554 ± 1.115 (1.24)	2.717 ± 1.453 (1.32)	1.952 ± 0.191 (1.10)	2.286 ± 0.255 (1.29)

indicates p < 0.05 versus group treated with anticancer drug only.

IC₅₀ values were determined by MTT assay as described in “materials and methods”, and were obtained from three independent experiments in triplicate.

Resistance fold (RF) was calculated from dividing the IC₅₀ values of parental cells or resistance cells by the IC₅₀ of parental cells in the of selonsertib or positive control inhibitor.